Financing ·
On August 18, 2026, AbbVie Inc. completed a $9.5 billion underwritten public offering of senior notes to fund its…
ABBVAbbVie Inc.
On August 18, 2026, AbbVie Inc. completed a $9.5 billion underwritten public offering of senior notes to fund its acquisition of Apogee Therapeutics, Inc. The issuance included $500 million in floating rate notes due 2028, $1 billion in 4.500% notes due 2028, $1.25 billion in 4.650% notes due 2030, $1.5 billion in 4.875% notes due 2031, $1.25 billion in 5.050% notes due 2033, $1.5 billion in 5.300% notes due 2036, $1 billion in 5.450% notes due 2038, $1.5 billion in 6.000% notes due 2056, and $500 million in 6.100% notes due 2066. Proceeds will primarily cover cash consideration for the Apogee acquisition and related expenses, with remaining funds allocated to general corporate purposes. The company operates in the biopharmaceutical industry.